As of May 27
| +0.62 / +9.98%|
The 6 analysts offering 12-month price forecasts for Aratana Therapeutics Inc have a median target of 12.00, with a high estimate of 15.00 and a low estimate of 9.00. The median estimate represents a +75.70% increase from the last price of 6.83.
The current consensus among 7 polled investment analysts is to Buy stock in Aratana Therapeutics Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.